

Weiheng Chen

PARTNER

Corporate
Hong Kong
Beijing
Shanghai

wchen@wsgr.com
852-3972-4988

FOCUS AREAS

Capital Markets
Corporate
Corporate Governance
Emerging Companies
Greater China
Mergers & Acquisitions
Private Equity
Special Purpose Acquisition
Companies (SPACs)

HIGHLIGHTS

- An Accomplished Transactional Practitioner**
Weiheng has represented clients in some of the largest and most significant M&A and capital market deals involving Chinese companies.
- Capital Markets Veteran**
Weiheng has represented issuers and underwriters in scores of securities offerings, including Hong Kong IPOs and HKSE listings, and NYSE and NASDAQ listings.
- Comprehensive Transactions Experience**
In addition to M&A and capital markets deals, Weiheng has substantial experience with private equity and venture capital investment, going-private, joint venture, and restructuring transactions.
- Broad Industry Experience**
Weiheng has represented clients in several business sectors, including the technology, media, telecom, healthcare, education, consumer, and financial industries.

EXPERIENCE

Weiheng Chen is a senior partner at Wilson Sonsini Goodrich & Rosati, where he heads the firm's Greater China practice.

Weiheng's practice is focused on cross-border mergers and acquisitions, private equity, and capital markets transactions in Asia. He has represented clients in connection with some of the largest and most significant M&A and capital market deals in a variety of industries, including technology, media and telecom, healthcare, education, consumer, and financial institutions. He also has worked on a large number of private equity and venture capital investment, going-private, joint venture, and restructuring transactions involving private equity and venture capital firms and multinational corporations. In addition, Weiheng has advised on many high-profile securities offerings, including Hong Kong IPOs and HKSE listings, and SEC-registered offerings and NYSE and NASDAQ listings. He has extensive experience representing both issuers and underwriters.

Weiheng started his legal career in New York, and has been residing in Hong Kong since 2003. He splits his time among the firm's offices in Asia, located in Hong Kong, Beijing, and Shanghai.

CREDENTIALS

Education

- LL.M., Harvard Law School

- Master of Jurisprudence and LL.B., Peking University Law School

Honors

- Designated as one of the "World's Leading Private Equity Lawyers" by IFLR/Euromoney
- Named to "The A-List: China's Elite Lawyers (Visionary category)" by *China Business Law Journal*
- Recognized as a "notable practitioner" by IFLR 1000

Admissions

- State Bar of New York
- Hong Kong

MATTERS

Select Representations

- Represented Boyu Capital, CDH Investments, Centurium Capital, Sequoia Capital, Silver Lake, Warburg Pincus, and other private equity and growth capital funds in connection with various investment and M&A transactions
- Represented technology and healthcare companies such as Tencent, DJI International, and WuXi Pharma in their various investment and financing matters
- Advised on the Hong Kong IPOs and HKSE listings of WuXi XDC, LEPU ScienTech Medical Technology, Angel Align Technology, Ascentage Pharma, WuXi AppTec, Wanka Online, WuXi Biologics, Rici Healthcare, Universal Medical, PW MedTech, Dongpeng Holdings, Alibaba.com, Bank of China, and China Shenhua Energy
- Advised on the U.S. public offerings and/or listings of Agora, Ebang International, Tencent Music Entertainment, X Financial, Opera Limited, Puxin Education, Bright Scholar, China Biologic Products, Autohome, China Nepstar Chain Drugstore, and Mindray Medical
- Provided underwriter-side representation to investment banks, including Goldman Sachs, Deutsche Bank, Morgan Stanley, CICC, Citi, JP Morgan, Credit Suisse, Bank of America, and UBS
- Represented Lumentum in the \$750 million acquisition of Cloud Light Technology Group
- Represented Boyu Capital in the acquisition of Quasar Medical
- Represented PW Medtech and the acquisition consortium in the \$4.6 billion going-private transaction of China Biologic Products, Inc.
- Represented Warburg Pincus and the acquisition consortium in the \$9.7 billion going-private transaction of 58.com
- Represented SilverLake-led investors in the \$2.3 billion PIPE investments in TAL Education
- Represented the acquisition consortium led by Yunfeng Capital and Alibaba and Boyu Capital in the \$1.5 billion going-private transaction of iKang Healthcare
- Represented the acquisition consortium in the HK\$5.6 billion going-private transaction of Dongpeng Holdings
- Represented the management shareholders and the acquisition consortium in the \$3.3 billion going-private transaction of WuXi PharmaTech
- Represented OmniVision Technologies in its \$1.9 billion acquisition by a Chinese consortium of investors
- Represented Integrated Silicon Solution Inc. in its \$640 million sale to a Chinese consortium of investors
- Represented the acquisition consortium in the \$1.9 billion going-private transaction of Shanda Games
- Represented the founder and the acquisition consortium in the \$3 billion going-private transaction of Giant Interactive
- Represent RDA Microelectronics in its \$900 million merger with Tsinghua Unigroup
- Represented TJOY Holdings in the \$400 million sale of its China skincare business to Coty, Inc.
- Represented State Grid International Development in its \$1.72 billion acquisition of power transmission assets in Brazil
- Represented Waste Management Inc. in its waste-to-energy joint venture with Shanghai Chentou Holdings in China
- Represented China Huaneng Group in its \$3 billion acquisition of Tuas Power in Singapore
- Represented C-BONS International in the €270 million sale of its China haircare business to Beiersdorf AG
- Represented CVC Partners in its sale of Adisseo France SAs to ChemChina
- Represented Bank of China in connection with its strategic sales to Royal Bank of Scotland, UBS, Temasek, and Asian Development Bank
- Represented Thomson in the combination of its global television business with TCL